Michael Severino, AbbVie president

Ab­b­Vie, rid­ing the Aduhelm af­ter­glow, hand­picks be­ta amy­loid drug for fur­ther R&D as it bails on tau

Al­though shroud­ed in con­tro­ver­sy, the FDA’s ap­proval of Bio­gen’s Aduhelm for Alzheimer’s dis­ease has opened the flood­gates for oth­er drug­mak­ers buy­ing in on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.